December 18th 2023
Expert oncologists highlight 2023’s transformative new targeted therapies and phase 3 data sets transforming the treatment paradigm in advanced prostate cancer.
Drs. Dorff and McKay discuss real-world data from DEAR trial comparing darolutamide, enzalutamide and apalutamide, providing clinical pearls on their experiences to optimize outcomes.
December 15th 2023
Dr. Tanya Dorff and Dr. Rana McKay discuss the mechanisms driving castration resistance and how emerging epigenetic biomarkers may transform prognosis.
Expert oncologists offer insights into conquering resistance, reimagining screening, and realizing the paradigm-shifting potential of advances in biomarker-driven precision medicine.
March 10th 2023
Tanya Dorff, MD, discusses key data supporting the use of intensified triplet regimens in metastatic hormone-sensitive prostate cancer, and remaining questions regarding the role of chemotherapy agents in these combinations.
January 12th 2023
Tanya Dorff, MD, discusses the exploration of triplet combination therapies in patients with metastatic hormone-sensitive prostate cancer.
January 10th 2023
Tanya Dorff, MD, discusses the investigation of PARP inhibitors in metastatic castration-resistant prostate cancer.
January 9th 2023
Closing out their review of the metastatic CRPC treatment paradigm, Tanya Dorff, MD, and Elisabeth Heath, MD, FACP, look toward future evolutions in care.
January 4th 2023
Tanya Dorff, MD, discusses remaining questions regarding sequencing in metastatic renal cell carcinoma.
January 2nd 2023
Tanya Dorff, MD, and Elisabeth Heath, MD, FACP, share perspective on the challenges inherent in delivering novel therapy to patients diagnosed with metastatic CRPC.
Comprehensive insight on factors that may influence the selection of cabazitaxel or radiotherapy for patients with metastatic castration-resistant prostate cancer.
December 26th 2022
A brief review of factors that may influence an academic or community physician’s choice to utilize cabazitaxel in the setting of metastatic castration-resistant prostate cancer.
Switching their focus to combination therapy in metastatic CRPC, expert oncologists review trial results from a study analyzing cabazitaxel/carboplatin therapy.
December 19th 2022
Tanya Dorff, MD, and Elisabeth Heath, MD, FACP, review data from the CARD trial and discuss the nuanced selection and sequencing of treatment in metastatic CRPC.
Expert perspectives on the PROSELICA trial, which helped inform optimal dosing strategies with cabazitaxel in metastatic castration-resistant prostate cancer.
December 12th 2022
Centering discussion on the use of cabazitaxel in metastatic CRPC, key opinion leaders consider optimal sequencing of therapy in light of the TROPIC clinical trial.
Expert oncologists Tanya Dorff, MD, and Elisabeth Heath, MD, FACP, reflect on the current treatment paradigm for patients with metastatic castration-resistant prostate cancer (mCRPC).
August 23rd 2022
Closing out their discussion on prostate cancer, expert panelists highlight which factors best inform selection of therapy for patients with mCRPC.
Panelists share insight on 177Lu-PSMA-617 and consider where it might fit into the treatment paradigm for metastatic castration-resistant prostate cancer.
August 16th 2022
Expert perspectives on how PARP inhibition will fit into the real-world management of patients with metastatic castration-resistant prostate cancer.